Skip to main content

Adamas Pharmaceuticals Inc

ADMSDelisted Nov 24, 2021
Industry
Pharmaceutical Preparations
SEC CIK
0001328143

Adamas Pharmaceuticals Inc was delisted on Nov 24, 2021; its insiders filed their last Form 4 on Nov 24, 2021; 63 institutions reported holding it in 13F filings for Q3 2021, worth $147.6M in total; no superinvestor held it.

Holders of 5% or more of ADMS

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Adamas Pharmaceuticals Inc, largest stake first. The change is against the holder's previous filing.

No holder currently reports owning 5% or more of Adamas Pharmaceuticals Inc on Schedule 13D or 13G.

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

13 Schedule 13D and 13G filings on Adamas Pharmaceuticals Inc, newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on ADMS
Filed (ET)FilerFormStakeChangeEvent dateFiling
Feb 15, 2022Armistice Capital, LLC13G/AOld format–––SEC
Feb 14, 2022Stonepine Capital Management, LLC13G/AOld format–––SEC
Jan 26, 2022Opaleye Management Inc.13G/AOld format–––SEC
Dec 10, 2021FMR LLC13G/AOld format–––SEC
Oct 20, 2021Hirschman Orin13G/AOld format–––SEC
Oct 19, 2021Magnetar Financial LLC13DOld format–New–SEC
Mar 10, 2021FMR LLC13GOld format–New–SEC
Mar 2, 2021Stonepine Capital Management, LLC13GOld format–––SEC
Feb 22, 2021Hirschman Orin13GOld format–New–SEC
Feb 16, 2021Armistice Capital, LLC13G/AOld format–––SEC
Feb 12, 2021Opaleye Management Inc.13G/AOld format–––SEC
Feb 12, 2021Macquarie Group Ltd13G/AOld format–––SEC
Feb 12, 2021Stonepine Capital Management, LLC13G/AOld format–––SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Adamas Pharmaceuticals Inc shares.

No Form 144 notices for Adamas Pharmaceuticals Inc are on file.